

Dear [Recipient's name],

The Association for Creatine Deficiencies is developing a Core Outcome Set (COS) to be used in clinical studies for creatine transporter deficiency (CTD) and guanidinoacetate methyltransferase (GAMT) deficiency.

Will you please share your perspectives on [CTD/GAMT] to help develop this Core Outcome Set?

The survey is LIVE now and will close on March 19.

<https://redcap.vanderbilt.edu/surveys/?s=HHJAFYYT3YKNMHXX>

If you have more questions about the project or the Delphi Survey, you can learn more by visiting <https://creatineinfo.org/cos>.

Thank you for your continued support of our family.

Kindest regards,
[Your name]